Gene expression profiles of disseminated breast cancer cells

Type: Transcriptome Analysis
Archiver: European Genome-Phenome Archive (EGA)

12 Datasets 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Samples
EGAD00001006359	A set of 56 EpCAM-positive cells derived from bone marrow aspirates of breast cancer patients or patients without a cancererous disease (30 cells from 21 M0-stage and 11 cells from five M1-stage breast cancer patients, 15 cells from seven non-cancer patients serving as controls). EpCAM-positive cells from breast cancer patients were considered disseminated tumor cells as they harbored copy number alterations and showed high expression of the epithelial marker EpCAM and the mammary luminal progenitor marker KIT in comparison to EpCAM-positive bone marrow cells from non-cancer patients. Paired-end RNA-Sequencing of the samples was performed on Illumina NovaSeq6000, raw data are provided in the Fastq format.	56
EGAD00010001960	Gene expression after cell culture, 12h Hyper-IL6 stimulated	3
EGAD00010001961	Gene expression after cell culture, 12h unstimulated	3
EGAD00010001962	Gene expression after cell culture, 24h unstimulated	3
EGAD00010001963	Gene expression after cell culture, 24h IL6+sgp130-Fc stimulated	3
EGAD00010001964	Gene expression after mammosphere culture, quiescent single cells	10
EGAD00010001965	Gene expression after cell culture, 24h IL6 stimulated	3
EGAD00010001966	Gene expression after mammosphere culture, non-label-retaining cells	5
EGAD00010001967	Gene expression after cell culture, 12h IL6 stimulated	3
EGAD00010001968	Gene expression after mammosphere culture, label-retaining cells	8
EGAD00010001969	Gene expression after cell culture, 24h Hyper-IL6 stimulated	3
EGAD00010001970	Gene expression after cell culture, 12h IL6+sgp130-Fc stimulated	3

Publications	Citations
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency. Werner-Klein M, Grujovic A, Irlbeck C, Obradović M, Hoffmann M, Koerkel-Qu H, Lu X, Treitschke S, Köstler C, Botteron C, Weidele K, Werno C, Polzer B, Kirsch S, Gužvić M, Warfsmann J, Honarnejad K, Czyz Z, Feliciello G, Blochberger I, Grunewald S, Schneider E, Haunschild G, Patwary N, Guetter S, Huber S, Rack B, Harbeck N, Buchholz S, Rümmele P, Heine N, Rose-John S, Klein CA. Nat Commun 11: 2020 4977	18

Publications

Citations

Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency.
Werner-Klein M, Grujovic A, Irlbeck C, Obradović M, Hoffmann M, Koerkel-Qu H, Lu X, Treitschke S, Köstler C, Botteron C, Weidele K, Werno C, Polzer B, Kirsch S, Gužvić M, Warfsmann J, Honarnejad K, Czyz Z, Feliciello G, Blochberger I, Grunewald S, Schneider E, Haunschild G, Patwary N, Guetter S, Huber S, Rack B, Harbeck N, Buchholz S, Rümmele P, Heine N, Rose-John S, Klein CA. Nat Commun 11: 2020 4977